indazoles has been researched along with Ovarian Neoplasms in 172 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (4.07) | 18.2507 |
| 2000's | 9 (5.23) | 29.6817 |
| 2010's | 88 (51.16) | 24.3611 |
| 2020's | 68 (39.53) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, SH; Kim, BG; Lim, MC; Noh, JJ; Park, SY; Shin, W | 1 |
| Chen, L; Davidson, B; Hershman, DL; Moss, HA; Wright, JD | 1 |
| Alwaqfi, RR; Bossler, AD; Guseva, NN; Ma, D; Ouyang, M; Samuelson, MI | 1 |
| Hawkes, C; Hurteau, J; Liu, J; Maiese, EM; Spalding, C; Travers, K; Walder, L | 1 |
| Braicu, E; Carbone, V; Cibula, D; Colombo, N; Frenel, JS; Ghizzoni, V; Giolitto, S; Giudice, E; Lorusso, D; Musacchio, L; Perri, MT; Pignata, S; Ricci, C; Salutari, V; Scambia, G; Zagouri, F | 1 |
| Bu, H; Chu, R; Feng, J; Kong, B; Li, J; Li, X; Li, Y; Liu, L; Maurer, J; Meng, J; Pan, X; Peng, J; Song, K; Yao, S; Yuan, Z; Zhang, Q; Zhang, T | 1 |
| Lee, A | 1 |
| Bellesoeur, A; Beuzeboc, P; Diéras, V; Neuzillet, C; Rodrigues, M; Saint-Ghislain, M; Salaün, H; Stern, MH | 1 |
| Azaïs, H; Bats, AS; Bentivegna, E; Blons, H; Delanoy, N; Durdux, C; Koual, M; Laurent-Puig, P; Le Frère-Belda, MA; Le Gac, M; Nguyen-Xuan, HT; Perkins, G | 1 |
| Liu, M; Liu, T; Sun, L; Tan, S; Tang, J; Xiao, W; Zhou, X | 1 |
| Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J | 1 |
| Alexandre, J; Kalbacher, E; Leary, A; Prulhière, K; Ray-Coquard, I; Selle, F | 1 |
| Guan, W; Perez, JM; Thomas, SN; Twigg, CAI | 1 |
| Agouridis, AP; Mamais, I; Michalinos, A; Pagkali, A | 1 |
| Artioli, G; Baumann, K; Bradley, WH; Calvert, PM; Dørum, A; Forget, F; Fuentes, J; González-Martín, A; Gupta, D; Hietanen, S; Kumar, A; Levy, T; Li, Y; Malinowska, IA; McCormick, C; Monk, BJ; Moore, RG; O'Cearbhaill, RE; O'Malley, DM; Pérez-Fidalgo, JA; Selle, F; Shahin, MS; Slomovitz, BM; Tusquets, I; Vulsteke, C | 1 |
| Asano, H; Enomoto, T; Ito, YM; Matsumura, N; Oda, K; Shimada, M; Watari, H; Yoshihara, K | 1 |
| Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M | 1 |
| Belotte, J; Clements, A; Fleming, EL; Gray, HJ; Gupta, D; Hamilton, E; Hardesty, MM; Keeton, EK; Konecny, GE; Krivak, TC; Moore, RG; Richardson, DL; Wang, P; Wright, GS | 1 |
| Feng, Y; Jia, H; Jiang, R; Jiang, W; Liu, J; Shi, T; Teng, Y; Wang, H; Wang, X; Wu, S; Xiang, L; Yu, A; Zang, R; Zhang, J; Zhang, P; Zhang, W; Zhang, Y; Zhu, J; Zhu, T; Zhu, Y | 1 |
| González-Martín, A; Gupta, D; Korach, J; Lechpammer, S; Matulonis, UA; Mirza, MR; Monk, BJ; Moore, KN; Wu, X; York, W | 1 |
| Barquin, A; Churruca, C; Constenla, M; Cueva, JF; de Juan, A; Estévez, P; Fernández, I; Gallego, A; García, Y; González-Martín, A; Guerra, E; Herrero, A; Juárez, A; Legerén, M; Manso, L; Marquina, G; Martín, C; Martín, T; Martínez Bueno, A; Maximiano, C; Palacio, I; Pardo, B; Quindós, M; Sánchez, L; Santaballa, A; Yubero, A | 1 |
| Buckley, L; González-Martin, A; Matulonis, UA; Mirza, MR; Monk, BJ; Moore, KN; Rimel, BJ; Wu, X | 1 |
| Chen, J; Fang, H; Pan, G; Wang, H; Wang, X; Zhang, Y | 1 |
| Chen, X; Cheng, X; Huang, X; Ju, X; Li, J; Li, Z; Liu, F; Shou, H; Tang, J; Tang, X; Wang, H; Wen, H; Wu, X; Yang, H; Yang, J; Zhang, L; Zhang, M; Zheng, F | 1 |
| Baumann, K; Baurain, JF; Calvert, PM; Denys, H; Follana, P; Gaba, L; Ghamande, SA; González-Martín, A; Graybill, WS; Guerra, EM; Gupta, D; Korach, J; Li, Y; Malinowska, IA; Mirza, MR; Monk, BJ; O'Malley, DM; Pisano, C; Prendergast, E; Rose, PG; Stephanie Yap, OW | 1 |
| Ikeda, Y; Kajiyama, H; Nei, T; Niimi, K; Tamauchi, S; Yoshikawa, N | 1 |
| Backes, F; Compton, N; Freyer, G; González-Martín, A; Graybill, W; Heitz, F; Lorusso, D; Malinowska, IA; McCormick, CC; Mirza, MR; Monk, BJ; Moore, RG; O'Cearbhaill, RE; Pothuri, B; Redondo, A; Shtessel, L; Vergote, I; Vulsteke, C | 1 |
| Cai, H; Cui, H; Hang, W; Hao, M; Hou, J; Huang, Y; Kong, B; Li, G; Li, N; Lin, A; Liu, J; Liu, Z; Lou, G; Lu, W; Pan, L; Pan, Y; Qu, P; Wang, C; Wang, J; Wang, K; Wang, L; Wu, L; Wu, X; Yang, H; Yang, Y; Yao, S; Yin, R; Zhang, Y; Zhao, H; Zhen, X; Zheng, H; Zhu, J; Zou, D | 1 |
| Ngan, RKC | 1 |
| Hashimoto, K; Kanao, H; Kawakami, K; Mori, Y; Shibata, N; Shimizu, H; Soejima, A; Sugisaki, T; Yamaguchi, M; Yokokawa, T; Yunokawa, M | 1 |
| Chen, B; Chen, J; He, A; Hou, W; Jia, M; Jiang, Z; Li, M; Miao, P; Qiu, S; Shao, Z; Shen, Y; Sun, W; Wu, X; Xu, J; Xu, X; Yuan, D; Zhang, B; Zhang, Y; Zhao, M; Zhou, Y; Zhu, T; Zhu, Y | 1 |
| Adams, S; Baines, A; Chon, HS; Cloven, NG; Coleman, RL; Dalton, H; Duska, LR; ElNaggar, AC; Gaillard, S; Holloway, RW; Huang, M; Konstantinopoulos, PA; Monk, BJ; Nelsen, LM; O'Cearbhaill, RE; O'Malley, DM; Randall, LM; Samnotra, V; Striha, A; Tarkar, A; Waggoner, S | 1 |
| Gao, Y; Hei, Y; Hou, J; Ji, D; Li, W; Lou, G; Milton, A; Wang, D; Wang, W; Wu, X; Xia, B; Yan, J; Yin, R; Zhang, J; Zhang, ZY; Zheng, H | 1 |
| Gray, S; Khor, XY; Yiannakis, D | 1 |
| Schorge, JO | 1 |
| Anttila, M; Åvall Lundqvist, E; Birrer, MJ; Bjørge, L; dePont Christensen, R; Dimoula, M; Hietanen, S; Krog Vistisen, A; Lindahl, G; Lund, B; Mäenpää, JU; Malander, S; Mirza, MR; Nyvang, GB; Peen, U; Roed, H; Staff, S; Werner, TL; Ør Knudsen, A | 1 |
| Banerjee, S; Benigno, B; Bessette, P; Buscema, J; Casado Herraez, A; Gil-Martin, M; Guy, H; Hardy-Bessard, AC; Kalbacher, E; Lau, S; Ledermann, JA; Lindahl, G; Mahner, S; Marmé, F; Matulonis, UA; Mirza, MR; Nøttrup, TJ; Travers, K; Walder, L; Wenham, RM; Woie, K | 1 |
| Bologna, A; Calvert, PM; Carrasco-Alfonso, MJ; Colombo, N; Del Campo, JM; du Bois, A; Floquet, A; Friedlander, M; Fujiwara, K; Hanker, LC; Harter, P; Herzog, TJ; Kim, JW; Lee, JY; Meunier, J; Mirza, MR; Monk, BJ; Pignata, S; Rau, J; Tsibulak, I; Vergote, I | 1 |
| Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y | 1 |
| Backes, F; Barretina-Ginesta, P; Baumann, K; Bradley, WH; Bruchim, I; DePont Christensen, R; Freyer, G; González-Martín, A; Graybill, W; Gupta, D; Haggerty, AF; Hoskins, P; Jardon, K; Li, Y; Lorusso, D; Lund, B; Malinowska, IA; Mangili, G; McCormick, C; Mirza, MR; Monk, BJ; Moore, RG; O'Cearbhaill, RE; Pothuri, B; Redondo, A; Rubio-Pérez, MJ; Shahin, MS; Sun, K; Vergote, I; Vulsteke, C | 1 |
| Gourd, E | 1 |
| Jin, X; Lv, H; Zhang, Z; Zhou, J | 1 |
| Amaravadi, RK; Bast, RC; Becker, SE; Heinzen, EP; Hou, X; Llombart-Cussac, A; Lu, Z; Matias-Guiu, X; Maurer, MJ; Oberg, AL; Pang, L; Poveda, A; Rask, P; Romero, I; Rubio, MJ; Santacana, M; Santiago-O'Farrill, JM; Weroha, SJ | 1 |
| Aboagye, EO; Arshad, M; Barwick, TD; Challapalli, A; Chambers, E; Chen, M; Cole, T; Dubash, S; Gabra, H; Inglese, M; Lozano-Kuehne, JP; Montes, A; Sharma, R; Tharakan, G; Valls, PO | 1 |
| Long, X; Zhou, Q; Zou, D | 1 |
| Walsh, CS | 1 |
| Longo, DL | 1 |
| Konstantinopoulos, PA; Vinayak, S | 1 |
| Rodrigues, M | 1 |
| Banerjee, S; Clamp, AR; Dive, C; Hall, M; Hasan, J; Jayson, GC; Lyon, AR; Morgan, RD; Orbegoso, C; Rustin, GJS; Taylor, S; Tugwood, J; Zhou, C | 1 |
| Bhatti, A; Horton, ER; Kerliu, L; Myruski, S; Pervanas, HC; Petrosius, P; Soni, P | 1 |
| Bai, J; Kristeleit, R; Monk, BJ; Moore, KN; Tewari, KS; Wolford, JE | 1 |
| Casado, J; Chen, YA; Chowdhury, D; D'Andrea, AD; Dezube, BJ; Färkkilä, A; Garcia, E; Graham, JR; Gulhan, DC; Hautaniemi, S; Jacobson, CA; Kochupurakkal, B; Konstantinopoulos, PA; Lako, A; Maliga, Z; Matulonis, UA; Munster, P; Nguyen, H; Park, PJ; Rodig, S; Santagata, S; Schapiro, D; Shapiro, GI; Sorger, PK; Swisher, EM; Yapp, C; Zhou, Y | 1 |
| Bajpai, J; Deodhar, K; Ghosh, J; Gulia, S; Gupta, S; Maheshwari, A; Rath, S; Shylasree, TS; Thakur, M | 1 |
| da Costa, A | 1 |
| Ai, Z; Bao, W; Chen, X; Feng, Y; Gao, W; Huang, H; Jia, H; Jiang, R; Jiang, W; Li, J; Li, Y; Liu, J; Luan, Y; Shi, T; Teng, Y; Wang, X; Wu, S; Yin, S; Yu, A; Zang, R; Zhang, J; Zhang, P; Zhang, W; Zhang, Y; Zhu, J; Zhu, T; Zhu, Y | 1 |
| Li, X; Liu, Z; Qu, Y; Su, J; Wang, X; Wang, Y; Wang, Z; Yang, M; Yu, L; Zeng, J; Zhu, Y | 1 |
| Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
| Ayari, H; Boissier, E; Cohen, R; Combe, P; Courbebaisse, M; Crespel, C; Delanoy, N; Karras, A; Lazareth, H; Mercadier-Riaz, E; Pallet, N; Thervet, E | 1 |
| Barrington, DA; Cohn, DE; Senter, L; Smith, HJ; Straughn, JM; Tubbs, C | 1 |
| Chase, DM; Eakin, CM; Ewongwo, A; Monk, BJ; Pendleton, L | 1 |
| Coleman, RL; Onstad, M; Westin, SN | 1 |
| Dockery, L; Moore, K; Randall, LM; Rimel, BJ | 1 |
| Barceló, IB; Benigno, B; Berton-Rigaud, D; Bessette, P; Buscema, J; de Jong, FA; du Bois, A; Dørum, A; Gupta, D; Herráez, AC; Herrstedt, J; Kalbacher, E; Lau, S; Ledermann, JA; Levy, T; Lorusso, D; Mahner, S; Matulonis, UA; Mirza, MR; Rimel, BJ; Vergote, I; Wang, P | 1 |
| Cui, Y; Lv, Q; Ma, L; Shen, G | 1 |
| Gabrail, N; Smith, C | 1 |
| Penn, CA; Walsh, CS; Wong, MS | 1 |
| Aoki, D; Hamanishi, J; Harano, K; Hasegawa, K; Hirasawa, T; Hori, K; Kase, Y; Komiyama, S; Kondo, E; Matsuura, M; Nakai, H; Nakamura, H; Nakamura, T; Okamoto, A; Sakata, J; Soeda, J; Sugiyama, T; Sumino, S; Suri, A; Tabata, T; Takehara, K; Takekuma, M; Yanagida, S; Yokoyama, Y | 1 |
| Abulizi, G; An, RF; Chen, LP; Chen, QH; Cui, H; Gao, YN; Hao, M; Hou, JM; Huang, XH; Huang, Y; Kong, BH; Li, GL; Liu, JH; Liu, ZL; Lou, G; Lu, WG; Lu, X; Mirza, MR; Tian, XF; Wang, DB; Wang, J; Wang, K; Wang, L; Wen, H; Wu, LY; Wu, XH; Yan, XJ; Yang, HY; Yang, JX; Yin, RT; Zhang, C; Zhang, Y; Zhou, Q; Zhu, JQ | 1 |
| Hamanishi, J; Hasegawa, K; Itamochi, H; Kase, Y; Matsumoto, T; Matsuura, M; Miura, K; Nagao, S; Nakai, H; Sumino, S; Suri, A; Takehara, K; Takeshima, N; Tanaka, N; Tokunaga, H; Ushijima, K; Watari, H; Yokoyama, Y | 1 |
| Hong, SH | 1 |
| Delaye, M; Rodrigues, M | 1 |
| Liu, MC; Sutedja, J; Tewari, KS | 1 |
| Ai, X; Chen, G; Cui, J; Ding, C; Dong, X; Gao, B; He, J; Hu, C; Hu, X; Huang, C; Jiang, L; Li, J; Li, X; Li, Y; Liao, W; Liu, A; Liu, C; Liu, X; Liu, Z; Lu, S; Ma, Z; Pan, Y; Shi, J; Song, Y; Wang, K; Wang, M; Wang, W; Xiong, J; Yang, N; Zhang, B; Zhang, D; Zhang, H; Zhang, X; Zhang, Y; Zhao, J; Zhou, J | 1 |
| Bahar, E; Kim, DC; Kim, HS; Kim, JY; Yoon, H | 1 |
| Chen, X; Cheng, X; Dai, Z; Gu, H; Guo, W; Ni, J; Wang, Y; Xu, X; Zhao, Q; Zhou, R | 1 |
| Chauhan, R; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Mathur, S; Sharma, A; Singh, M; Sreenivas, V | 1 |
| Chan, AL; Lang, HC; Leung, JH; Lo, HF; Wang, SY | 1 |
| Duan, P; Fan, L; Gao, Q; Qu, W; Ren, M; Shen, Y; Silwal, BM | 1 |
| Scott, LJ | 1 |
| Dinkic, C; Eichbaum, M; Fricke, HC; Gebauer, G; Grischke, EM; Lenz, F; Marme, F; Rom, J; Schmidt, M; Schneeweiss, A; Sohn, C; Wallwiener, M | 1 |
| Lorusso, D; Sabatucci, I | 1 |
| Beijnen, JH; Gebretensae, A; Hughes, L; Kansra, V; Rosing, H; Sanghvi, M; Schellens, JHM; Tibben, MM; van Andel, L; Zhang, Z | 1 |
| Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC | 1 |
| Barrett, C; Bologna, A; Buck, M; Calvert, P; Debruyne, P; du Bois, A; Friedlander, M; Herzog, TJ; Hilpert, F; Kim, JW; King, MT; Lee, CK; Lesoin, A; Malander, S; Meier, W; Monk, BJ; Petru, E; Poveda, A; Rau, J; Scambia, G; Shimada, M | 1 |
| Agarwal, S; Burris, H; Kansra, V; Moore, K; Patel, MR; Zhang, ZY | 1 |
| Matulonis, UA; Mirza, MR; Moore, KN | 1 |
| Avogadri-Connors, F; Booth, L; Cutler, RE; Dent, P; Lalani, AS; Poklepovic, A; Roberts, JL; Samuel, P | 1 |
| Longoria, TC; Tewari, KS | 1 |
| Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L | 1 |
| Berek, JS; Berton-Rigaud, D; Colombo, N; Ellard, S; Ghatage, P; Gonzalez-Martin, A; Guo, W; Hazard, S; Ledermann, J; Lesoin, A; Madry, R; Mahner, S; Matulonis, UA; Mirza, MR; Peen, U; Pineda, M; Redondo, A; Reinthaller, A; Rosengarten, O; Sehouli, J; Vergote, I | 1 |
| Konstantinopoulos, PA; Matulonis, UA | 1 |
| Essel, KG; Moore, KN | 1 |
| Benedetti Panici, P; Tomao, F; Tomao, S | 1 |
| Coleman, RL; Richardson, DL; Sill, MW | 1 |
| Aoki, D; Chiyoda, T | 1 |
| Duggan, ST; Heo, YA | 1 |
| O'Cearbhaill, RE | 1 |
| Monga, DK; Patibandla, NS | 1 |
| Baldini, C; Banerjee, S; Battisti, NML; Dumas, L; Kadambi, S; Lichtman, SM; Liposits, G; Loh, KP; Soto-Perez-de-Celis, E | 1 |
| Fisher, M; Guy, H; Walder, L | 2 |
| Nugent, E; Smith, JA; Tomasino, T; Tran, AT; Zhong, L | 1 |
| Wu, L; Zhong, L | 1 |
| Coleman, RL; Kurnit, KC; Westin, SN | 1 |
| Banerjee, S; Bover, I; Dørum, A; Fabbro, M; Follana, P; Goffin, F; Harter, P; Hazard, SJ; Hellman, K; Mahner, S; Matulonis, UA; Mirza, MR; Moore, KN; Pineda, MJ; Provencher, D; Shapira-Frommer, R; Tinker, AV; Tognon, G; Vázquez, IP; Wenham, RM | 1 |
| Bai, H; Jiang, X; Li, W; Li, X; Zhang, Z | 1 |
| Federico, L; Feng, B; Feng, N; Hanke, J; Ma, X; Marszalek, JR; Mikule, K; Mills, GB; Ramaswamy, S; Sun, K; Vellano, CP; Wang, J; Wang, Z; Xiao, Y | 1 |
| Cohn, DE; Ehrisman, JA; Foote, JR; Havrilesky, LJ; Jewell, E; Liang, MI; Secord, AA | 1 |
| Azodi, M; Berek, JS; Chan, JK; Cloven, N; Cristea, M; DiSilvestro, P; Fleming, GF; Geller, MA; Li, Y; Luptakova, K; Matei, DE; Matulonis, UA; Miller, DS; Monk, BJ; Moore, KN; Oza, AM; Rimel, BJ; Secord, AA; Sun, K; Wahner Hendrickson, AE | 1 |
| Fagotti, A; Marchetti, C; Scambia, G | 1 |
| Campbell, JD; Chapman, RH; Kumar, VM; McQueen, RB; Whittington, MD | 1 |
| Bedel, J; Cameron, T; Goble, S; Isaacson, J; Maloney, L; Wallace, K | 1 |
| Arora, S; Benigno, B; Berek, JS; Canzler, U; Del Campo, JM; Follana, P; Gil-Martin, M; Gilbert, L; Hazard, SJ; Lesoin, A; Lund, B; Mahner, S; Malander, S; Matulonis, UA; Mirza, MR; Monk, BJ; Oza, AM; Provencher, D; Waters, J; Wenham, RM; Woie, K | 1 |
| Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; de Bono, JS; Kaye, SB; Lord, CJ; Mateo, J; Oaknin, A; Serra, V; Tutt, A | 1 |
| Aguilera, J; Behbakht, K; Bitler, BG; Brennecke, EP; Cittelly, DM; Ferguson, R; Joglar, AM; Kim, H; McMellen, A; Moldovan, GL; Nurmemmedov, E; Sikora, MJ; Thakar, T; Watson, ZL; Wilson, H; Yamamoto, TM | 1 |
| Bernards, R; Caumanns, JJ; de Jong, S; Jalving, M; Kol, A; Meersma, GJ; van der Zee, AGJ; van Wijngaarden, A; Wisman, GBA | 1 |
| Åvall-Lundqvist, E; Bergmann, TK; Birrer, MJ; Bjørge, L; Brøsen, K; Christensen, RD; Jørgensen, M; Lassen, U; Mäenpää, J; Malander, S; Mau-Sørensen, M; Mirza, MR; Nielsen, F; Roed, H | 1 |
| Amatangelo, MD; Conejo-Garcia, JR; Garipov, A; Li, H; Speicher, DW; Zhang, R | 1 |
| Baird, RD; Carpenter, CL; Chatterjee, M; de Bono, JS; Forster, M; Gevensleben, H; Hylands, L; Iannone, R; Kaye, SB; Kreischer, N; Loughney, J; Miranda, S; Moreno, V; Omlin, A; Riisnaes, R; Sandhu, SK; Schelman, WR; Sun, L; Thway, K; Toniatti, C; Wenham, RM; Wilding, G | 1 |
| Chou, LC; Chung, CH; Huang, CH; Huang, LJ; Kuo, SC; Lee, FY; Lee, JC; Lien, JC; Way, TD; Wu, JC | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Chen, W; Ding, L; Hou, H; Li, X; Li, Z; Liu, T; Zhao, L | 1 |
| Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P | 1 |
| Konstantinopoulos, PA; Liu, JF; Matulonis, UA | 1 |
| McGuire, WP; Oliver, KE | 1 |
| Baumann, KH; Calvert, P; Canzler, U; Colombo, N; Crescenzo, R; del Campo, JM; Diaz-Padilla, I; du Bois, A; Floquet, A; Friedlander, M; Fujiwara, K; Harter, P; Herzog, TJ; Kim, BG; Kim, JH; Kim, JW; Kimmig, R; Kurzeder, C; Lesoin, A; Marth, C; Mirza, MR; Mitrica, I; Monk, BJ; Mouret-Reynier, MA; Pignata, S; Pujade-Lauraine, E; Rau, J; Ray-Coquard, I; Scambia, G; Schade-Brittinger, C; Shimada, M; Vasey, P; Vergote, I; Wang, Q; Zang, R | 1 |
| Barrett, C; Calvert, P; Colombo, N; Crescenzo, RJ; del Campo, JM; du Bois, A; Fiane, B; Floquet, A; Friedlander, M; Herzog, TJ; Isonishi, S; Kim, JW; Meier, W; Mitrica, I; Monk, BJ; Pisano, C; Reinthaller, A; Vergote, I; Wang, K | 1 |
| Glickson, JD; Heitjan, DF; Leeper, DB; Nath, K; Nelson, DS; Zhou, R | 1 |
| Rahman, A | 1 |
| Chua, CC; Earwood, CB; Firdaus, ID; Hainsworth, JD | 1 |
| Deng, LL; Lin, P; Liu, Y; Lu, C; Qin, Z; Sun, L | 1 |
| Liu, XJ; Lu, H; Mo, YS; Shi, BK; Sun, JX; Wang, SR; Yang, XS | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Arcangeli, V; Brandes, AA; Cecere, SC; Cinieri, S; Daniele, G; Di Maio, M; Di Napoli, M; Gallo, C; Lorusso, D; Maltese, G; Mosconi, AM; Orditura, M; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Ricci, C; Salutari, V; Sambataro, D; Scambia, G; Tamberi, S | 1 |
| Devriese, LA; Giantonio, BJ; Kerklaan, BM; Lane, S; Langenberg, M; Legenne, P; Lolkema, MP; Mergui-Roelvink, M; Mykulowycz, K; Nol-Boekel, A; Schellens, JH; Smith, DA; Stoebenau, J; Voest, EE; Wissel, P; Witteveen, PO | 1 |
| Banerjee, S; McLachlan, J | 1 |
| Cox, CJ; Crescenzo, R; du Bois, A; Harter, P; Kim, BG; Kim, JW; Kong, BH; Liu, JH; Mahner, S; Mitrica, I; Ngan, HY; Park, SY; Shoji, T; Takano, T; Wang, KL; Wang, Q; Wei, LH; Wu, LY; Wu, Q; Zhang, P; Zhu, JQ | 1 |
| Barrett, C; Berton-Rigaud, D; Chan, JK; Colombo, N; Del Campo, JM; du Bois, A; Forget, F; Friedlander, M; Harter, P; Heitz, F; Herzog, TJ; Imhof, M; Jobanputra, M; Johnson, T; King, K; Mirza, MR; O'Donnell, D; Park, SY; Shimada, M; Stinnett, S; Xu, CF; Zamagni, C | 1 |
| Afshar-Kharghan, V; Armaiz-Pena, GN; Bottsford-Miller, J; Burns, AR; Cho, MS; Choi, HJ; Dalton, HJ; Gharpure, KM; Gutschner, T; Haemmerle, M; Han, HD; Hansen, JM; Lopez-Berestein, G; Mangala, LS; Nagaraja, AS; Nick, AM; Pecot, CV; Pradeep, S; Rupaimoole, R; Sood, AK; Stone, RL; Taylor, ML; Wu, SY; Zand, B | 1 |
| AlHilli, MM; Becker, MA; Flatten, KS; Haluska, P; Harrell, MI; Harrington, SC; Hawthorne, KM; Hou, X; Hurley, RM; Kalli, KR; Kaufmann, SH; Maurer, MJ; McKinstry, S; Meng, XW; Oberg, AL; Swisher, EM; Weroha, SJ; Wilcoxen, KM | 1 |
| Agarwal, S; Balser, JP; Ben-Baruch, NE; Benigno, B; Berek, JS; Buscema, J; Christensen, RD; du Bois, A; Dørum, A; Fabbro, M; Follana, P; Gilbert, L; González-Martín, A; Herrstedt, J; Ledermann, JA; Lorusso, D; Mądry, R; Mahner, S; Marth, C; Matulonis, UA; Mirza, MR; Monk, BJ; Oza, AM; Redondo, A; Rimel, BJ; Rosenberg, P; Tinker, AV; Vergote, I | 1 |
| Fujiwara, K; Hasegawa, K; Kozawa, E; Nishikawa, T; Yabuno, A; Yasuda, M; Yoshida, H | 1 |
| Bae, J; Kim, YJ; Lee, CS; Lee, SJ | 1 |
| Alix, S; Box, G; Chuckowree, I; Clarke, PA; De Haven Brandon, A; Di Stefano, F; Eccles, SA; Folkes, A; Gowan, S; Hayes, A; Henley, AT; Lensun, L; McDonald, E; Patel, S; Pergl-Wilson, G; Raynaud, FI; Robson, A; Saghir, N; Sheldrake, P; Shuttleworth, S; Valenti, M; Wan, NC; Workman, P; Zhyvoloup, A | 1 |
| Carroll, AR; Coleman, RL; Dumble, M; Jennings, N; Kamat, AA; Kumar, R; Lin, YG; Lu, C; Matsuo, K; Merritt, WM; Nick, AM; Shahzad, MM; Sood, AK; Spannuth, WA; Stone, RL; Zhang, S | 1 |
| Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P | 1 |
| Friedlander, M; Hancock, KC; Hodge, JP; Lager, JJ; Ma, B; Matthys, GM; Messing, MJ; Rischin, D; Stringer, CA | 1 |
| Belvin, M; Edgar, KA; Friedman, LS; Guan, J; Kassees, R; Prior, WW; Sampath, D; Wallin, JJ | 1 |
| Amiji, M; Duan, Z; Milane, L | 1 |
| Kim, W; Kim, YJ; Lee, CS; Myung, SC | 1 |
| Barranger, E; Camus, M; Eveno, C; le Maignan, C; Pocard, M; Soyer, P | 1 |
| Behbakht, K; Gu, H; Sheng, Q; Spillman, MA; Wang, Y | 1 |
| Bischofs, E; Eichbaum, M; Eickhoff, R; Fehm, T; Fersis, N; Fricke, HC; Gebauer, G; Lenz, F; Mayer, C; Schmidt, M; Schneeweiss, A; Sohn, C; Solomayer, E; Wallwiener, M | 1 |
| Raynaud, FI; Workman, P | 1 |
| Kim, W; Kim, YJ; Kwak, SW; Lee, CS; Lee, JJ; Lee, MS; Lee, SA; Myung, SC; Park, ES | 1 |
| Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Papaldo, P | 1 |
| Kibble, A; Shumoogam, J; Walker, K | 1 |
| Blagg, BS; Chakrasali, R; Georg, GI; Hadden, MK; Heckert, LL; Hornbaker, K; Hughes, J; Jakkaraj, SR; Kinzy, TG; Ozturk, SB; Smith, SK; Tash, JS | 1 |
| Kaye, SB | 1 |
| Brunetti, I; Conte, PF; Dargenio, F; Fanucchi, A; Gadducci, A; Giannessi, PG; Muttini, MP | 1 |
| Fukunaka, N; Ishioka, S; Itoh, E; Kitajima, Y; Kudo, R; Sagae, S; Sato, K | 1 |
| Bottalico, C; de Lena, M; Guerrieri, A; Lorusso, V; Micelli, G; Palmisano, F | 1 |
| Bottalico, C; Brandi, M; Catino, A; De Lena, M; De Mitrio, A; Gargano, G; Guida, M; Latorre, A; Leone, B; Lorusso, V; Vallejo, C | 1 |
| Bearzatto, A; De Marco, C; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N | 1 |
| Blessing, JA; Hoffman, MA; Morgan, M | 1 |
| Caporusso, L; Catino, A; Crucitta, E; De Lena, M; Fanizza, G; Gargano, G; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D | 1 |
| Blessing, JA; Hoffman, MA; Nuñez, ER | 1 |
| Costa, A; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N | 1 |
| Frühauf, S; Zeller, WJ | 1 |
28 review(s) available for indazoles and Ovarian Neoplasms
| Article | Year |
|---|---|
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Topics: Adult; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines | 2021 |
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Topics: Breast Neoplasms; DNA Damage; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Indoles; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Recombinational DNA Repair | 2022 |
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; DNA Damage; DNA Repair-Deficiency Disorders; Endometrial Neoplasms; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Papillomavirus Infections; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Uterine Cervical Neoplasms | 2022 |
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines | 2022 |
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
Topics: Clinical Trials, Phase II as Topic; Female; Genital Neoplasms, Female; Homologous Recombination; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2022 |
Niraparib treatment for patients with
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2022 |
Safety and management of niraparib monotherapy in ovarian cancer clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2023 |
The Efficacy and Safety of Pazopanib Plus Chemotherapy in Treating Recurrent or Persistent Ovarian Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Sulfonamides | 2023 |
First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two 'long responder' case reports and review of the current literature.
Topics: Asian People; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2023 |
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2020 |
Latest clinical evidence of maintenance therapy in ovarian cancer.
Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic | 2020 |
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Topics: Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2020 |
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Approval; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Maintenance Chemotherapy; Mutation; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Randomized Controlled Trials as Topic; Recombinational DNA Repair; United States; United States Food and Drug Administration | 2020 |
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Topics: Angiogenesis Inhibitors; Bevacizumab; Clinical Trials as Topic; Female; Humans; Indazoles; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Analysis; Treatment Outcome | 2017 |
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Topics: Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; Indazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2018 |
Niraparib for the treatment of ovarian cancer.
Topics: Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Practice Guidelines as Topic | 2018 |
Niraparib: A Review in Ovarian Cancer.
Topics: Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations | 2019 |
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carbazoles; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Phthalazines; Phthalimides; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Topics: Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2019 |
A decade of clinical development of PARP inhibitors in perspective.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genomic Instability; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
PARP inhibitors in ovarian cancer: current status and future promise.
Topics: Antineoplastic Agents; Benzimidazoles; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2014 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Pazopanib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Disease-Free Survival; Female; Humans; Indazoles; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2015 |
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Indazoles; Lung Neoplasms; Male; Ovarian Neoplasms; Safety | 2003 |
47 trial(s) available for indazoles and Ovarian Neoplasms
| Article | Year |
|---|---|
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Immune Checkpoint Inhibitors; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea | 2022 |
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Piperidines | 2022 |
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines; Platinum | 2022 |
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Topics: Body Weight; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prospective Studies | 2023 |
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Progression-Free Survival | 2023 |
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Progression-Free Survival | 2023 |
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2023 |
Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer.
Topics: Female; Humans; Indazoles; Male; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2020 |
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Topics: Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Disease Progression; Female; Humans; Hypertension; Indazoles; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Proteinuria; Thrombocytopenia | 2019 |
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Pyrimidines; Quality of Life; Sulfonamides; Treatment Outcome; Young Adult | 2019 |
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Nausea; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality of Life; Survival Analysis | 2019 |
[
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Ovarian Neoplasms; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Pyrimidines; Sulfonamides | 2020 |
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Stilbenes; Sulfonamides; Survival Rate | 2020 |
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CD8-Positive T-Lymphocytes; DNA Mutational Analysis; Drug Monitoring; Female; Gene Amplification; Humans; Indazoles; Interferons; Macrophages; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Recombinational DNA Repair; Single-Cell Analysis; Treatment Outcome; Tumor Microenvironment | 2020 |
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
Topics: Adolescent; China; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Positron Emission Tomography Computed Tomography; Quality of Life | 2020 |
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Topics: Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2020 |
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
Topics: Female; Homologous Recombination; Humans; Indazoles; Japan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
Topics: Female; Humans; Indazoles; Japan; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines | 2021 |
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines | 2021 |
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides | 2021 |
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Indazoles; Leukopenia; Liver Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Pyrimidines; Sulfonamides | 2017 |
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Breast Neoplasms; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Radioactive Tracers; Tandem Mass Spectrometry | 2018 |
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Placebos; Progression-Free Survival; Proto-Oncogene Mas; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance th
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Reported Outcome Measures; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides; Time-to-Treatment | 2018 |
Safety and dose modification for patients receiving niraparib.
Topics: Administration, Oral; Adult; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Incidence; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platelet Count; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Retrospective Studies; Risk Factors; Thrombocytopenia | 2018 |
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Reported Outcome Measures; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adolescent; Adult; Aged; BRCA1 Protein; BRCA2 Protein; Canada; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Time Factors; United States; Young Adult | 2019 |
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2019 |
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2019 |
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Cohort Studies; Female; Follow-Up Studies; Heterozygote; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Prostatic Neoplasms; Tissue Distribution | 2013 |
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
Topics: Angiogenesis Inhibitors; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2014 |
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Topics: Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Endpoint Determination; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides | 2015 |
Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Indazoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Pyrimidines; Sulfonamides | 2015 |
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrimidines; Sulfonamides; Treatment Outcome | 2015 |
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome; Young Adult | 2015 |
Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.
Topics: Adult; Aged; Aged, 80 and over; Asia, Eastern; Asian People; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor Receptor-1; Young Adult | 2018 |
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genome-Wide Association Study; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; White People; Young Adult | 2016 |
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Disease-Free Survival; Double-Blind Method; Female; Genes, BRCA1; Germ-Line Mutation; Homologous Recombination; Humans; Indazoles; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Piperidines; Platinum Compounds; Young Adult | 2016 |
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; CA-125 Antigen; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; Survival Rate | 2010 |
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Pyrimidines; Sulfonamides | 2011 |
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Epirubicin; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy | 1994 |
Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Drug Synergism; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms | 1997 |
Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms | 2000 |
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms | 2001 |
97 other study(ies) available for indazoles and Ovarian Neoplasms
| Article | Year |
|---|---|
Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Tapering; Feasibility Studies; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Staging; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Adherence to PARP inhibitor therapy among women with ovarian cancer.
Topics: Female; Humans; Indazoles; Medication Adherence; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies | 2021 |
PTCH1-GLI1 Fusion-Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib.
Topics: Female; Gene Fusion; Hedgehog Proteins; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Zinc Finger Protein GLI1 | 2021 |
Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
Topics: Adult; Aged; Budgets; Cost-Benefit Analysis; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States | 2021 |
Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
Topics: B7-H1 Antigen; Female; Humans; Immunity; Indazoles; Ovarian Neoplasms; Piperidines | 2021 |
Chronic stress induces platinum and Niraparib resistance in mouse models of ovarian cancer.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Models, Biological; Ovarian Neoplasms; Piperidines; Platinum; Stress, Psychological | 2022 |
Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Topics: Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Indazoles; Indoles; Mass Spectrometry; Mitochondria; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Proteomics; Signal Transduction | 2022 |
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
Topics: Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2022 |
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non-interventional study in China.
Topics: China; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2023 |
Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation.
Topics: BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ-Line Mutation; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms | 2023 |
Serum Creatinine Elevation as a Risk Factor for Niraparib-induced Hematologic Toxicity.
Topics: Anemia; Creatinine; Female; Humans; Indazoles; Neutropenia; Ovarian Neoplasms; Risk Factors; Thrombocytopenia | 2023 |
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
Topics: Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2023 |
Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases.
Topics: Aged; Brain Neoplasms; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Treatment Outcome | 2019 |
Chemotherapy-free, but not quite free chemotherapy.
Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum | 2019 |
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Topics: BRCA1 Protein; BRCA2 Protein; Disease Progression; Drug Administration Schedule; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors | 2019 |
Niraparib improves progression-free survival in ovarian cancer.
Topics: Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Randomized Controlled Trials as Topic | 2019 |
Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arginine; Aspartic Acid; Betulinic Acid; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Female; Glycine; Humans; Hydrogen-Ion Concentration; Indazoles; Leukocyte Count; Ligands; Mice; Micelles; Oligopeptides; Ovarian Neoplasms; Pentacyclic Triterpenes; Tissue Distribution; Triterpenes; Xenograft Model Antitumor Assays | 2019 |
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Indazoles; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Xenograft Model Antitumor Assays | 2020 |
Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer.
Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum | 2019 |
Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.
Topics: Cystadenocarcinoma, Serous; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Precision Medicine | 2019 |
BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-Reply.
Topics: Antibodies, Monoclonal, Humanized; Female; Humans; Indazoles; Mutation; Ovarian Neoplasms; Piperidines; Recombinational DNA Repair | 2020 |
[PARP inhibitors in first-line of ovarian cancers].
Topics: Benzimidazoles; Clinical Trials as Topic; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2020 |
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indazoles; Indoles; Infusions, Intravenous; Markov Chains; Models, Statistical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; United States | 2020 |
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Pyrimidines; Retrospective Studies; Sulfonamides | 2020 |
PARP Inhibitors in Ovarian Cancer.
Topics: Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2020 |
YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Centrioles; Female; Humans; Indazoles; Mitosis; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2020 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2020 |
Nephrotoxicity Associated With Niraparib.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Kidney Diseases; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Risk Factors | 2020 |
Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
Topics: Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality-Adjusted Life Years | 2020 |
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community Health Centers; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Female; Follow-Up Studies; Gynecology; Humans; Indazoles; Indoles; Medical Oncology; Medication Therapy Management; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Workload | 2020 |
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
Topics: Fallopian Tube Neoplasms; Female; Humans; Indazoles; Molecular Targeted Therapy; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Treatment Outcome | 2020 |
Overexpression of NDRG2 promotes the therapeutic effect of pazopanib on ovarian cancer.
Topics: Apoptosis; Biomarkers, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2021 |
Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
Topics: Adenosine Diphosphate Ribose; Breast Neoplasms; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Thiazoles; Thiophenes; Thrombocytopenia | 2020 |
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Topics: Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Ovarian Epithelial; Computing Methodologies; Cost-Benefit Analysis; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Maintenance Chemotherapy; Medicare; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2020 |
How to start niraparib in real-world Asian ovarian cancer patients?
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2021 |
[New drug approval: Olaparib and niraparib - first line in ovarian cancer].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Female; Humans; Indazoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy.
Topics: Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2021 |
Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Humans; Indazoles; Mitochondria; Nuclear Proteins; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Signal Transduction; Synthetic Lethal Mutations; Twist-Related Protein 1 | 2021 |
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Topics: Adult; Aged; China; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines | 2022 |
Niraparib: First Global Approval.
Topics: Adult; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Approval; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2017 |
[Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.]
Topics: Antineoplastic Agents; Disease-Free Survival; DNA Breaks, Double-Stranded; DNA Repair; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2017 |
PARP inhibitors for ovarian cancer.
Topics: Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome | 2017 |
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Area Under Curve; Dietary Fats; Drug Monitoring; Fasting; Female; Food-Drug Interactions; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Therapeutic Equivalency | 2018 |
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinolines | 2018 |
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment | 2018 |
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Paclitaxel and Pazopanib in Ovarian Cancer.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2018 |
Paclitaxel and Pazopanib in Ovarian Cancer-Reply.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2018 |
PARP inhibitors and quality of life in ovarian cancer.
Topics: Double-Blind Method; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2018 |
Using PARP Inhibitors in Advanced Ovarian Cancer.
Topics: Anemia; Creatinine; Drug Administration Schedule; Drug Interactions; Exanthema; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Heart Rate; Humans; Hypertension; Indazoles; Leukopenia; Mutation; Myelodysplastic Syndromes; Nasopharyngitis; Nausea; Ovarian Neoplasms; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia; Transaminases; Vomiting | 2018 |
Niraparib - A promising drug with hematological toxicity.
Topics: Aged, 80 and over; Female; Hematologic Diseases; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Topics: Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality-Adjusted Life Years; Survival Rate; United States | 2019 |
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Topics: Clinical Decision-Making; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States | 2018 |
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States | 2019 |
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Topics: Animals; Antibodies; Base Sequence; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Gene Expression Profiling; Humans; Immunotherapy; Indazoles; Interferons; Mice; Mice, Inbred C57BL; Mutation; Neoplasm Transplantation; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Receptor | 2019 |
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Indazoles; Indoles; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Randomized Controlled Trials as Topic | 2019 |
Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2019 |
Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".
Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2019 |
Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.
Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2019 |
Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".
Topics: Cost-Benefit Analysis; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2019 |
Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Indazoles; Indoles; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Wnt Signaling Pathway | 2019 |
Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Benzoxazoles; Biomarkers, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mice, Nude; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Indazoles; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polycomb Repressive Complex 2; Pyridones; Tumor Microenvironment | 2013 |
CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Furans; HSP90 Heat-Shock Proteins; Humans; Indazoles; Mice; Mice, SCID; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2013 |
Inactivation of von Hippel-Lindau increases ovarian cancer cell aggressiveness through the HIF1α/miR-210/VMP1 signaling pathway.
Topics: Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Ovarian Neoplasms; Von Hippel-Lindau Tumor Suppressor Protein | 2014 |
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome | 2014 |
Ovarian cancer and antiangiogenic therapy: caveat emptor.
Topics: Angiogenesis Inhibitors; Female; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2014 |
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.
Topics: Acids; Adenosine Triphosphate; Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Synergism; Energy Metabolism; Female; Humans; Hydrogen-Ion Concentration; Indazoles; Intracellular Space; Magnetic Resonance Spectroscopy; Male; Mice, Nude; Monocarboxylic Acid Transporters; Ovarian Neoplasms; Prostatic Neoplasms; Symporters; Xenograft Model Antitumor Assays | 2015 |
Maintenance pazopanib in ovarian cancer.
Topics: Female; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Sulfonamides | 2014 |
Hypoxia promotes HO-8910PM ovarian cancer cell invasion via Snail-mediated MT1-MMP upregulation.
Topics: Animals; Cell Culture Techniques; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Collagen Type I; Extracellular Matrix; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indazoles; Matrix Metalloproteinase 14; Neoplasm Invasiveness; Neoplasm Metastasis; Ovarian Neoplasms; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Up-Regulation | 2015 |
Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.
Topics: Amino Acids; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Indazoles; Ketoconazole; Molecular Docking Simulation; Ovarian Neoplasms; Oxidation-Reduction; Pyrimidines; Sulfonamides | 2016 |
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
Topics: Adenosine Diphosphate; Animals; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Platelets; Cell Hypoxia; Cell Line, Tumor; Female; Focal Adhesion Kinase 1; Humans; Indazoles; Mice; Mice, Knockout; Neoplasm Proteins; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Topics: DNA-Binding Proteins; Female; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic | 2016 |
Niraparib Slows Ovarian Cancer Progression.
Topics: BRCA1 Protein; BRCA2 Protein; Clinical Trials, Phase III as Topic; Disease Progression; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome | 2016 |
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.
Topics: Aged; Antineoplastic Agents; Carcinosarcoma; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Uterine Neoplasms | 2017 |
Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; Enzyme Activators; Enzyme-Linked Immunosorbent Assay; Female; Guanylate Cyclase; Humans; Indazoles; Neoplasm Proteins; Ovarian Neoplasms | 2009 |
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Topics: Administration, Oral; Animals; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Female; Furans; Glioblastoma; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Sulfonamides; Thiophenes; TOR Serine-Threonine Kinases; Umbilical Veins; Xenograft Model Antitumor Assays | 2009 |
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Therapy; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Kaplan-Meier Estimate; Mice; Models, Biological; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Humans; Indazoles; Mice; Mutation; Neoplasm Transplantation; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides | 2010 |
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Resistance, Multiple; ErbB Receptors; Female; Humans; Indazoles; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Polymers | 2011 |
Guanylate cyclase activator YC-1 enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells via activation of apoptosis-related proteins.
Topics: Apoptosis; Biomarkers, Tumor; Caspase 8; Cell Line, Tumor; Enzyme Activators; Female; Guanylate Cyclase; Humans; Indazoles; Membrane Potential, Mitochondrial; Microtubule-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; TNF-Related Apoptosis-Inducing Ligand | 2011 |
Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication.
Topics: Anastomosis, Surgical; Angiogenesis Inhibitors; Anti-Bacterial Agents; Carcinoma; Colectomy; Female; Humans; Hysterectomy; Indazoles; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Peritoneal Neoplasms; Pyrimidines; Salpingectomy; Sulfonamides; Surgical Wound Dehiscence; Treatment Outcome | 2011 |
Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cadherins; Cell Line, Tumor; Cell Movement; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Indazoles; Mutant Proteins; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Sulfonamides; Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2012 |
Discovering and developing PI3 kinase inhibitors for cancer: rapid progress through academic-biotech-pharma interactions.
Topics: Animals; Enzyme Inhibitors; Female; Furans; Glioblastoma; Humans; Indazoles; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; Thiophenes | 2011 |
Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Carcinoma, Ovarian Epithelial; Caspases; Cell Line, Tumor; Cell Nucleus; Chalcones; Drug Interactions; Enzyme Activation; Female; Guanylate Cyclase; Humans; Indazoles; Neoplasm Proteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteolysis; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Biomedical Research; CA-125 Antigen; Clinical Trials as Topic; Dasatinib; Female; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Ovarian Neoplasms; Pyrimidines; Snake Venoms; Sulfonamides; Thiazoles; Treatment Outcome | 2007 |
Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells.
Topics: Administration, Oral; Amino Acid Sequence; Animals; Binding Sites; Cell Line; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Indazoles; Interleukin-1alpha; Male; Models, Biological; Molecular Sequence Data; Ovarian Neoplasms; Peptide Elongation Factor 1; Rats; Sertoli Cells; Spermatogenesis-Blocking Agents; Testis; Transcription, Genetic | 2008 |
New drugs for ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bevacizumab; BRCA2 Protein; Carboplatin; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A | 2008 |
[The prevention of CDDP-induced emesis with granisetron].
Topics: Antiemetics; Cisplatin; Female; Granisetron; Humans; Indazoles; Infusions, Intravenous; Nausea; Ovarian Neoplasms; Uterine Neoplasms; Vomiting | 1993 |
An on-line semi-automated solid-phase extraction procedure for high-performance liquid chromatographic determination of lonidamine in serum.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Humans; Indazoles; Ovarian Neoplasms | 1995 |
Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mitotic Index; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Protamine Kinase; Tubulin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Topics: Cell Cycle; Cell Survival; Cisplatin; Cross-Linking Reagents; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Female; Humans; In Vitro Techniques; Indazoles; Ovarian Neoplasms; Tumor Cells, Cultured | 1992 |
New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
Topics: Animals; Crown Ethers; DNA, Neoplasm; Drug Screening Assays, Antitumor; Ethers, Cyclic; Ethylnitrosourea; Female; Indazoles; Organometallic Compounds; Organophosphorus Compounds; Organoplatinum Compounds; Ovarian Neoplasms; Rats; Ruthenium; Titanium | 1991 |